Mer­ck KGaA in talks to sell its biosim­i­lars R&D ops as shake­out looms

The biosim­i­lars busi­ness is just get­ting es­tab­lished, but the shake­out among a group of high-pow­ered ri­vals is al­ready tak­ing shape.

Mer­ck KGaA CEO Ste­fan Os­chmann told re­porters this morn­ing that the com­pa­ny is deep in talks to sell its biosim­i­lars group, ac­cord­ing to Reuters, dick­er­ing on a unit that has been tar­get­ing some fa­mil­iar block­busters like Hu­mi­ra (Ab­b­Vie), Rit­ux­an (Roche) and Neu­las­ta (Am­gen).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER